CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) SVP Marcia Belvin sold 19,512 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $0.60, for a total transaction of $11,707.20. Following the sale, the senior vice president now directly owns 248,636 shares in the company, valued at $149,181.60. The trade was a 7.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
CytomX Therapeutics Stock Up 0.4 %
Shares of NASDAQ CTMX traded up $0.00 during trading on Monday, hitting $0.67. The company had a trading volume of 695,281 shares, compared to its average volume of 2,636,110. The firm has a market capitalization of $53.65 million, a price-to-earnings ratio of 3.94 and a beta of 1.05. The stock has a fifty day simple moving average of $0.76 and a two-hundred day simple moving average of $0.98. CytomX Therapeutics, Inc. has a fifty-two week low of $0.56 and a fifty-two week high of $5.85.
CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.45. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. The company had revenue of $38.09 million for the quarter, compared to analyst estimates of $13.53 million. On average, analysts anticipate that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the stock. StockNews.com upgraded shares of CytomX Therapeutics from a "hold" rating to a "buy" rating in a research report on Monday, March 10th. Wedbush restated an "outperform" rating and issued a $5.00 price target on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a report on Friday, March 7th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $5.02.
Read Our Latest Stock Report on CTMX
Hedge Funds Weigh In On CytomX Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the business. Connor Clark & Lunn Investment Management Ltd. raised its holdings in CytomX Therapeutics by 10.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 280,593 shares of the biotechnology company's stock valued at $331,000 after acquiring an additional 26,373 shares during the last quarter. FMR LLC grew its position in shares of CytomX Therapeutics by 17.3% in the third quarter. FMR LLC now owns 284,307 shares of the biotechnology company's stock valued at $335,000 after purchasing an additional 41,949 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its holdings in shares of CytomX Therapeutics by 1.1% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,524,076 shares of the biotechnology company's stock valued at $1,798,000 after purchasing an additional 16,359 shares during the last quarter. Geode Capital Management LLC lifted its position in CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company's stock worth $948,000 after buying an additional 34,032 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in CytomX Therapeutics during the third quarter worth $104,000. 67.77% of the stock is owned by hedge funds and other institutional investors.
CytomX Therapeutics Company Profile
(
Get Free Report)
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Further Reading
Before you consider CytomX Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.
While CytomX Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
